Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

NCT05314998 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

394

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Oxaliplatin
DRUG: Irinotecan
DRUG: Folinic acid
DRUG: 5-fluorouracil
DRUG: Gemcitabine
DRUG: Capecitabine

Sponsor

John Neoptolemos

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]